

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

ANNOUNCEMENT MADE IN ACCORDANCE WITH RULE 13.18 OF THE LISTING RULES SEVEN-YEAR LONG-TERM LOAN FACILITIES

This announcement is made in accordance with the requirement under Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors (the “**Board**”) of Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”) is pleased to announce that, on 6 December 2024, the Company and Weigao International Holding Corporation Pte. Limited, a wholly owned subsidiary of the Company (collectively, the “**Borrowers**”), respectively entered into loan agreements (the “**Loan Agreements**”) with International Finance Corporation, a member of the World Bank Group and the largest global development institution focused on the private sector in developing countries (“**IFC**”), pursuant to which loans with an aggregated principal amount of no more than USD250,000,000 (equivalent to approximately HK\$1,946,000,000) (the “**Loans**”) will be made available to the Borrowers on the terms and conditions set forth in the Loan Agreements. Each of the Borrowers shall repay the Loans in 7 approximately equal semi-annual instalments starting on 15 March 2029, with the final instalment due on 15 March 2032. The Board considers that the Loans will facilitate the Company’s expansion in South East Asia as well as investments in capital expenditures and research and development in China.

* For identification purpose only

Under the Loan Agreements, unless otherwise agreed by IFC, if at any time and for any reason 威高集團有限公司 (Weigao Holding Company Limited*) (“**Weigao Holding**”) ceases to own (directly or indirectly) at least 35% of both the economic and voting interests in the Company’s share capital (determined on a fully diluted basis), the Borrowers shall prepay the outstanding principal amount of the Loans in full immediately.

As at the date of this announcement, Weigao Holding directly and indirectly holds 2,099,755,676 shares in the Company, representing approximately 45.94% of the total issued share capital of the Company.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Long Jing
Chairman

6 December 2024

Weihai, Shandong, the PRC

As at the date of this announcement, the Board comprises:

Mr. Long Jing (*Executive Director*)

Mr. Cong Rinan (*Executive Director*)

Mr. Lu Junqiang (*Executive Director*)

Mr. Wang Daoming (*Executive Director*)

Mr. Tang Zhengpeng (*Non-executive Director*)

Mr. Chen Lin (*Non-executive Director*)

Ms. Yan Xia (*Non-executive Director*)

Mr. Li Guohui (*Independent Non-executive Director*)

Mrs. Meng Hong (*Independent Non-executive Director*)

Mr. Li Qiang (*Independent Non-executive Director*)

Mr. Sun Heng (*Independent Non-executive Director*)